文献速递中医妇科针灸推拿中药与中成药合理使用

神阙穴中医治疗原发性痛经的有效性与安全性:随机对照试验的系统评价与Meta分析

Effectiveness and Safety of Chinese Medicine at Shenque (CV 8) for Primary Dysmenorrhea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Chin J Integr Med · 2022-04-15

该系统评价与Meta分析纳入24项RCT共2614例原发性痛经患者,评估神阙穴中药贴敷、艾灸或联合脐疗对比西药或安慰剂的效果。结果显示脐疗在降低疼痛视觉模拟评分、改善症状缓解率及整体月经症状评分方面优于西药,未见重大不良事件,但纳入试验方法学质量普遍较差。

要点

  • 神阙穴脐疗可降低原发性痛经患者VAS疼痛评分,优于西药对照。
  • 脐疗在3个月随访时症状缓解率优于西药,整体月经症状评分亦改善。
  • 未见重大不良事件报告,但纳入试验方法学质量整体较差。

核心结论

  • 神阙穴脐疗在减轻原发性痛经疼痛和改善整体症状方面似乎比西药更有效。
  • 上述发现需设计良好、样本量充足的临床试验进一步证实。

研究设计与样本

  • 系统评价与Meta分析,检索CNKI、VIP、SinoMed、Wanfang、MEDLINE、Cochrane Library、Embase、Web of Science及美国NIH国际临床试验注册库,从建库至2021年4月1日。
  • 纳入评估神阙穴脐疗治疗原发性痛经疗效的随机对照试验,共纳入24项RCT、2614例参与者。
  • 干预措施包括神阙穴中药贴敷、艾灸或联合脐疗(至少2种刺激方式),对照为安慰剂或西药。
  • 使用RevMan 5.4软件进行数据分析,在线GRADEpro工具评估证据确定性。

主要发现

  • 与安慰剂相比,脐疗在治疗结束时降低整体月经症状评分有显著效果(均数差:-0.82,95%CI:-1.00至-0.64,n=90;1项RCT)。
  • 与西药相比,脐疗在治疗结束时降低VAS疼痛强度更优(标准化均数差:-0.64,95%CI:-1.22至-0.06,I²=80%,n=262;3项RCT)。
  • 与西药相比,脐疗在3个月随访时症状缓解率更优(风险比:1.94,95%CI:1.47至2.56,n=1527,I²=38%;13项RCT)。
  • 与西药相比,脐疗在治疗结束时改善整体月经症状评分更优(标准化均数差:-0.67,95%CI:-0.90至-0.45,I²=63%,n=990;12项RCT)。
  • 亚组分析显示脐疗与西药相比效果更优或等效,未报告重大不良事件。

关键数值与推荐

  • 与安慰剂比,整体月经症状评分均数差-0.82(95%CI -1.00至-0.64,n=90;1项RCT)。
  • 与西药比,VAS疼痛评分标准化均数差-0.64(95%CI -1.22至-0.06,I²=80%,n=262;3项RCT)。
  • 与西药比,3个月随访症状缓解率风险比1.94(95%CI 1.47至2.56,n=1527,I²=38%;13项RCT)。
  • 与西药比,整体月经症状评分标准化均数差-0.67(95%CI -0.90至-0.45,I²=63%,n=990;12项RCT)。

临床怎么用

  • 对于原发性痛经患者,可考虑在神阙穴实施中药贴敷、艾灸或联合脐疗以缓解疼痛和改善症状。
  • 脐疗可作为西药治疗的替代或补充选项,但需结合患者意愿和具体情况。
  • 临床决策时应知晓现有证据方法学质量较差,需谨慎解读疗效估计。

局限性

  • 纳入试验的方法学质量整体较差。
  • 部分合并分析存在显著异质性(如VAS疼痛评分I²=80%)。
  • 结论需设计良好、样本量充足的临床试验进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary dysmenorrhea (PD) is the most common complaint associated with menstruation and affects up to three-quarters of women at some stage of their reproductive life. In Chinese medicine, navel therapy, treatment provided at Shenque (CV 8), is used as a treatment option for PD. OBJECTIVE: To evaluate the effect of navel therapy on pain relief and quality of life in women with PD, compared with Western medicine (WM). METHODS: China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), SinoMed and Wanfang Database, MEDLINE, the Cochrane Library, Embase, Web of Science, and the International Clinical Trial Registry of the U.S. National Institutes of Health were searched from their inceptions to April 1, 2021. Randomized controlled trials (RCTs) assessing therapeutic effects of navel therapy on PD were eligible for inclusion. RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool. RESULTS: Totally 24 RCTs involving 2,614 participants were identified. Interventions applied to acupuncture point CV 8 included: herbal patching, moxibustion or combined navel therapy (using at least 2 types of stimulation). Compared to placebo, there was a significant effect in favor of navel therapy on reducing overall menstrual symptom scores at the end of treatment [mean difference: -0.82, 95% confidence interval (CI): -1.00 to -0.64, n=90; 1 RCT]. As compared with Western medicine, navel therapy had a superior effect on pain intensity as assessed by Visual Analogue Scale at the end of treatment [standardized mean difference (SMD): -0.64, 95% CI: -1.22 to -0.06, I2=80%, n=262; 3 RCTs]; on symptom resolution rate at 3-month follow-up (risk ratio: 1.94, 95% CI: 1.47 to 2.56, n=1527, I2=38%; 13 RCTs); and on global menstrual symptoms score at the end of treatment (SMD: -0.67, 95% CI: -0.90 to -0.45, I2=63%, n=990; 12 RCTs). Subgroup analyses showed either a better or an equivalent effect comparing navel therapy with Western medicine. No major adverse events were reported. The methodological quality of included trials was poor overall. CONCLUSIONS: Navel therapy appears to be more effective than Western medicine in decreasing menstrual pain and improving overall symptoms of PD. However, these findings need to be confirmed by well-designed clinical trials with adequate sample size (Systematic review registration at PROSPERO, No. CRD42021240350).

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Yan LJ, Fang M, Zhu SJ, et al. Effectiveness and Safety of Chinese Medicine at Shenque (CV 8) for Primary Dysmenorrhea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chin J Integr Med. 2022. PMID: 35426052. doi:10.1007/s11655-022-3319-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。